CD-117 Immunohistochemistry at Test Zone Diagnostic Center

Understanding CD-117 Immunohistochemistry at Test Zone Diagnostic Center

CD-117 Immunohistochemistry (IHC) is a highly specialized, state-of-the-art laboratory investigation used in histopathology to detect the expression of the CD117 protein in tissue specimens. CD117, also known as c-KIT or tyrosine-protein kinase KIT, is a receptor tyrosine kinase encoded by the KIT proto-oncogene. This protein plays a fundamental role in cell signal transduction, regulating essential cellular processes such as proliferation, survival, differentiation, and migration. In clinical practice, the identification of CD117 expression is of paramount diagnostic, prognostic, and therapeutic significance, particularly in the field of oncology.

At Test Zone Diagnostic Center in Sargodha, Pakistan, CD-117 Immunohistochemistry is performed using advanced automated staining platforms and high-affinity monoclonal antibodies. The primary clinical utility of this test lies in its exceptional sensitivity and specificity for diagnosing Gastrointestinal Stromal Tumors (GISTs), which are the most common mesenchymal neoplasms of the gastrointestinal tract. Historically, distinguishing GISTs from other spindle cell neoplasms of the abdomen—such as leiomyomas, leiomyosarcomas, schwannomas, and desmoid fibromatosis—posed a significant diagnostic challenge. The advent of CD-117 IHC revolutionized this process, as approximately 95% of GISTs exhibit strong, diffuse CD117 positivity, whereas most other mesenchymal tumors are negative.

Beyond GISTs, CD-117 Immunohistochemistry is an indispensable tool for evaluating several other pathological conditions. It is used to identify and quantify mast cells in cases of suspected systemic mastocytosis or mast cell leukemia. It also serves as a key marker in the diagnostic panels for seminomas and dysgerminomas (germ cell tumors), certain subtypes of acute myeloid leukemia (AML), and adenoid cystic carcinomas. By providing precise molecular-level characterization of tumor cells, CD-117 IHC enables pathologists at Test Zone Diagnostic Center to deliver definitive diagnoses that directly guide personalized treatment strategies, including targeted therapies with tyrosine kinase inhibitors like imatinib mesylate (Gleevec).

Clinical Procedure: What to Expect

Patient Preparation

Because CD-117 Immunohistochemistry is a laboratory test performed on tissue specimens that have already been extracted from the body, there is no direct preparation required for the patient on the day of the laboratory analysis itself. However, the initial acquisition of the tissue sample requires preparation depending on the surgical or biopsy procedure used:

• Biopsy or Surgical Resection: If the tissue sample has not yet been obtained, patients must follow the specific pre-operative instructions provided by their surgeon, gastroenterologist, or interventional radiologist. This may include fasting (NPO) for endoscopic procedures, temporary cessation of anticoagulant medications, and routine pre-operative blood tests.
• Submission of Existing Blocks/Slides: If the biopsy was performed at another facility, patients can bring the formalin-fixed paraffin-embedded (FFPE) tissue blocks and corresponding hematoxylin and eosin (H&E) stained slides directly to Test Zone Diagnostic Center in Sargodha for CD-117 IHC testing. Ensure all pathology records and clinical histories are submitted alongside the specimen.
• Medication History: It is crucial to inform the clinical team of any ongoing treatments, especially prior tyrosine kinase inhibitor therapy, as this can occasionally influence tumor morphology and antigen expression.

During the Procedure

The laboratory phase of CD-117 Immunohistochemistry is a multi-step, highly controlled technical process executed by skilled histotechnologists and evaluated by consultant pathologists at Test Zone Diagnostic Center:

• Specimen Processing and Sectioning: The submitted tissue block (FFPE) is mounted on a microtome, and ultra-thin sections measuring approximately 3 to 4 micrometers are cut. These sections are carefully transferred onto specialized, positively charged glass slides to ensure tissue adherence during subsequent processing.
• Deparaffinization and Rehydration: The slides are heated and treated with clearing agents (such as xylene) to remove the paraffin wax, followed by graded alcohols to rehydrate the tissue sections back to an aqueous state.
• Antigen Retrieval: Formalin fixation creates methylene bridges that can mask the CD117 antigen. To reverse this, slides undergo Heat-Induced Epitope Retrieval (HIER) using a specialized buffer solution (typically citrate or EDTA buffer) at a controlled high temperature to expose the CD117 epitopes.
• Antibody Incubation: The tissue sections are incubated with a highly specific primary monoclonal or polyclonal antibody directed against the CD117 antigen. If the CD117 protein is present in the tissue, the antibody binds specifically to it.
• Detection and Visualization: After washing away unbound primary antibodies, a secondary detection system (usually a polymer conjugated with horseradish peroxidase) is applied. A chromogen substrate, typically 3,3'-diaminobenzidine (DAB), is then added, which reacts to produce a highly visible, insoluble brown precipitate at the site of antigen-antibody binding.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to visualize cell nuclei (staining them blue), dehydrated, cleared, and sealed with a coverslip.
• Microscopic Evaluation: A consultant pathologist examines the stained slides under a high-power light microscope to evaluate the intensity, pattern (membranous, cytoplasmic, or perinuclear dot-like), and percentage of cells expressing CD117.

When is a CD-117 Immunohistochemistry Performed?

Suspected Gastrointestinal Stromal Tumors (GISTs)

Physicians request CD-117 IHC when a patient presents with an abdominal mass, gastrointestinal bleeding, unexplained anemia, or obstructive symptoms, and subsequent imaging or endoscopy reveals a submucosal tumor in the stomach, small intestine, or colon. Because GISTs require entirely different surgical and oncological management compared to epithelial carcinomas or smooth muscle tumors, establishing CD117 positivity is critical to confirming the diagnosis and initiating targeted therapy.

Differential Diagnosis of Spindle Cell Neoplasms

Mesenchymal tumors of the abdomen and retroperitoneum often look remarkably similar under standard hematoxylin and eosin (H&E) staining. Pathologists utilize CD-117 IHC as part of a diagnostic panel to differentiate GISTs from leiomyosarcomas (which are typically CD117 negative, SMA positive), schwannomas (CD117 negative, S100 positive), and desmoid fibromatosis (CD117 negative, beta-catenin positive). This differentiation is vital, as the prognosis and treatment protocols for these conditions diverge significantly.

Diagnosis and Subtyping of Mast Cell Disorders

CD-117 is highly expressed on the surface of normal and neoplastic mast cells. When patients present with clinical signs of systemic mastocytosis—such as recurrent anaphylaxis, flushing, abdominal pain, osteopenia, or unexplained cytopenias—a bone marrow biopsy or skin biopsy is performed. CD-117 IHC is used to identify abnormal aggregates of mast cells in the bone marrow or extracutaneous organs, helping to confirm systemic mastocytosis according to World Health Organization (WHO) criteria.

Evaluation of Testicular and Ovarian Germ Cell Tumors

In young adults presenting with testicular masses or pelvic tumors, CD-117 IHC is employed to classify germ cell tumors. Seminomas of the testes and dysgerminomas of the ovaries characteristically show strong, diffuse membranous CD117 expression. This marker helps distinguish these tumors from embryonal carcinomas and yolk sac tumors, which are generally CD117 negative, thereby ensuring appropriate chemotherapy selection.

Characterization of Acute Myeloid Leukemia (AML)

In hematopathology, CD-117 IHC or flow cytometry is performed on bone marrow aspirates and trephine biopsies of patients suspected of having leukemia. CD117 is a marker of hematopoietic progenitor cells and is expressed in approximately 60% to 70% of AML cases. Identifying CD117 expression assists in lineage assignment, subtyping immature myeloid neoplasms, and monitoring minimal residual disease (MRD) post-treatment.

What Does a CD-117 Immunohistochemistry Detect?

CD-117 Immunohistochemistry detects the presence, localization, and distribution of the c-KIT receptor tyrosine kinase within tissue cells. Specifically, the test identifies:

• Strong, diffuse cytoplasmic staining in neoplastic cells, characteristic of classic Gastrointestinal Stromal Tumors (GISTs).
• Distinct membranous staining patterns, commonly observed in seminomas and dysgerminomas.
• Perinuclear dot-like (Golgi-zone) positivity, which is a highly specific diagnostic pattern seen in a subset of GISTs.
• The presence of abnormal, dense clusters of mast cells (defined as aggregates of 15 or more mast cells) in bone marrow biopsies, confirming systemic mastocytosis.
• Spindle cell neoplasms lacking CD117 expression, pointing toward alternative diagnoses such as leiomyosarcoma, schwannoma, or solitary fibrous tumor.
• Expression of CD117 in myeloid blasts, aiding in the diagnosis of acute myeloid leukemia (AML) and distinguishing it from acute lymphoblastic leukemia (ALL).
• Focal or weak CD117 expression in normal breast epithelium, skin melanocytes, and basal cells of the prostate.
• Hyperplasia of the Interstitial Cells of Cajal (ICC) in the gastrointestinal tract, which are the pacemaker cells from which GISTs originate.
• Strong CD117 expression in adenoid cystic carcinomas of the salivary glands, which can have prognostic implications.
• CD117 expression in chromophobe renal cell carcinoma, helping differentiate it from other renal oncocytomas.
• The persistence of CD117-positive tumor cells in post-treatment biopsies, indicating residual disease or resistance to tyrosine kinase inhibitors.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center in Sargodha, we understand that waiting for pathology results can be an anxious time for patients and their families. Because immunohistochemistry involves complex, multi-stage laboratory processing—including tissue sectioning, antigen retrieval, antibody incubation, and expert microscopic review—the turnaround time for CD-117 IHC is typically 3 to 5 working days from the time the specimen is received in our laboratory.

Once the staining is complete, our consultant histopathologists carefully analyze the slides alongside the patient's clinical history and primary H&E stains. The finalized, highly detailed diagnostic report is uploaded directly to our secure online portal. Patients and referring physicians can access and download the reports from the comfort of their homes via the Test Zone Diagnostic Center website or through our dedicated WhatsApp reporting service. Physical copies of the report and the stained glass slides can also be collected directly from our main facility in Sargodha.

CD-117 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Gastrointestinal Stromal Tissue	Focal, weak staining in normal Interstitial Cells of Cajal (ICC)	Strong, diffuse cytoplasmic or membranous CD117 positivity (indicative of GIST)
Smooth Muscle Tumors (Leiomyoma/Leiomyosarcoma)	Completely negative for CD117 expression	Rare, extremely weak focal staining (re-evaluation of diagnosis required)
Neural Tumors (Schwannoma)	Negative for CD117 expression	Negative staining (confirms non-GIST lineage when S100 is positive)
Bone Marrow (Mast Cells)	Scattered, isolated CD117-positive mast cells (<1% of cellularity)	Dense aggregates of >15 atypical, spindle-shaped mast cells (Systemic Mastocytosis)
Testicular Tissue (Germ Cells)	Staining limited to normal spermatogonia	Diffuse, strong membranous CD117 positivity in tumor cells (Seminoma)
Ovarian Tissue	Negative in normal ovarian stroma and follicles	Strong CD117 positivity in tumor nests (Dysgerminoma)
Myeloid Blasts (Bone Marrow)	Minimal expression in early progenitor cells only	Increased percentage of CD117-positive myeloblasts (Acute Myeloid Leukemia)
Salivary Gland Tissue	Normal ductal epithelium may show weak staining	Overexpression of CD117 in tumor cells (Adenoid Cystic Carcinoma)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for CD-117 Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology laboratory is led by highly qualified, consultant histopathologists with extensive experience in oncological diagnostics and immunohistochemical interpretation.
• Advanced Staining Technology: We utilize state-of-the-art, automated IHC staining systems that ensure precise temperature control, consistent antigen retrieval, and highly reproducible staining quality.
• Rigorous Quality Control: Test Zone Diagnostic Center adheres to strict internal and external quality assurance protocols, running positive and negative tissue controls with every batch of CD-117 stains.
• Comprehensive Diagnostic Panels: We offer a wide range of complementary IHC markers (such as DOG1, CD34, SMA, Desmin, S100, and Ki-67) to provide a complete diagnostic workup for complex cases.
• Patient-Focused Care: We prioritize patient comfort and convenience, offering clear guidance on specimen submission and hassle-free diagnostic processing.
• Convenient Location in Sargodha: Located centrally in Sargodha, Punjab, our diagnostic center is easily accessible to patients from the city and surrounding districts.
• Digital Report Access: Patients and oncologists can access highly detailed pathology reports online or via WhatsApp, facilitating prompt clinical decision-making.
• Commitment to Accurate Diagnosis: We are dedicated to providing timely, evidence-based, and highly accurate diagnostic insights that form the foundation of successful cancer therapy.